Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant dimeglumine injection vs aprepitant capsules for prevention of highly emetogenic chemotherapy-induced nausea and vomiting
CTR20170270Phase 3Completed
- Sponsor
- Roxin Pharmaceutical
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Roxin Pharmaceutical. Started Mar 2017; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20170270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170270.